早发冠心病患者血浆MCP-1水平检测及其临床意义

The plasma concentration of monocyte chemoattractant protein-1 and clinical significance in patients with premature heart disease

目的观察早发冠心病患者血浆单核细胞趋化蛋白-1(MCP-1)水平及其临床意义。方法应用酶联免疫吸附法分别检测急性冠脉综合征(ACS组,n=44)、稳定性心绞痛(SAP组,n=41)及对照组(n=87)患者血浆MCP-1水平,并进行比较,对血浆MCP-1水平与病变冠脉支数、心肌肌钙蛋白Ⅰ、载脂蛋白AⅠ的关系进行分析。结果ACS组血浆MCP-1水平高于SAP组和对照组(P=0.001),而SAP组与对照组之间血浆MCP-1差异无统计学意义(P>0.05)。在不同冠脉病变支数患者之间血浆MCP-1差异无统计学意义(P>0.05)。MCP-1水平与心肌肌钙蛋白Ⅰ呈正相关(r=0.371,P=0.010),与载脂蛋白AⅠ呈负相关(r=-0.233,P=0.007)。结论早发冠心病ACS患者血浆MCP-1水平明显增高,是斑块不稳定性的标志之一。

Objective To study the relationship between plasma concentration of monocyte chemoattracrant protein-1 （ MCP-1 ） and patients with premature heart disease. Methods MCP-1 was measured by means of enzyme linked immonosorbent assay（ELISA） in 44 patients with acute coronary syndrome （ACS） ,41 patients with stable angina pectoris（ SAP） and 87 patients in control group. Results Plasma concentration of MCP-1 was significantly higher in ACS group than that in SAP group and control group（P =0. 001 ）. There was no sig- nificant difference in the levels of plasma MCP-1 between SAP and control group（ P 〉 0.05 ）. There was no significant difference in the levels of plasma MCP-1 among patients with one, two or three diseased coronary vessels（P 〈 0.05 ）. Plasma level of MCP-1 was positively correlated with cTn Ⅰ （r = 0.371 ,P = 0.010）, and negtively correlated with apoA Ⅰ （r = -0.233 ,P = 0.007）. Conclusion Plasma MCP-1 level is significantly elevated in ACS, indicating its role as a marker predicting the unstability of plaques.